Literature DB >> 7711982

Treatment of depression with flupenthixol in terminally ill patients.

M Lloyd-Williams.   

Abstract

In recent years, there has been much interest in the psychological well-being of cancer patients (Buckberg et al., 1980; Plumb & Holland, 1977; Razavi et al., 1990; Grassi et al., 1989). It is recognized that if depression is detected and treated, the quality of life for the patient is improved (Holland, 1987; Valentine & Saunders, 1989). Many patients are treated with tricyclic anti-depressants which work well in some cases, but these drugs can have the disadvantage of taking 3 weeks before any improvement in the mood of the patient is observed. They can also cause unpleasant side-effects, e.g. dry mouth, urinary retention and constipation. These symptoms are often already present in the terminally ill and their exacerbation can make these drugs unacceptable to such patients. Two cases of depression which were detected on admission to a hospice and which were successfully treated with flupenthixol dihydrochloride are reported.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7711982

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  1 in total

1.  The antipsychotic agent flupentixol is a new PI3K inhibitor and potential anticancer drug for lung cancer.

Authors:  Chao Dong; Yin Chen; Hongjian Li; Yi Yang; Hongtao Zhang; Kunbin Ke; Xi-Nan Shi; Xu Liu; Ling Li; Jing Ma; Hsiang-Fu Kung; Ceshi Chen; Marie Chia-Mi Lin
Journal:  Int J Biol Sci       Date:  2019-06-02       Impact factor: 6.580

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.